You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

High MET amplification

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

NSCLC Trial in United States (capmatinib)

Recruiting
  • Non-small Cell Lung Cancer
  • La Jolla, California
  • +7 more
Oct 5, 2022

NSCLC Trial (HS-10241+ Almonertinib, Pemetrexed + Cisplatin /Carboplatin)

Not yet recruiting
  • Non-Small Cell Lung Cancer
  • HS-10241+ Almonertinib
  • Pemetrexed + Cisplatin /Carboplatin
  • (no location specified)
Oct 29, 2023

Lung Non-Small Cell Carcinoma Trial (Amivantamab, Biospecimen Collection, Computed Tomography)

Not yet recruiting
  • Lung Non-Small Cell Carcinoma
  • Amivantamab
  • +3 more
  • (no location specified)
Oct 30, 2023

Advanced Gastric Adenocarcinoma Trial in Seoul (Volitinib)

Completed
  • Advanced Gastric Adenocarcinoma
  • Seoul, Korea, Republic of
    Samsung Medical center
Jun 13, 2022

Non-squamous Non-small-cell Lung Cancer, Stage IV NSCLC, ROS1 Gene Rearrangement Trial in Toronto (Crizotinib)

Recruiting
  • Non-squamous Non-small-cell Lung Cancer
  • +4 more
  • Toronto, Ontario, Canada
    Princess Margaret Cancer Centre
Jan 8, 2023

NSCLC Trial in Shanghai (Savolitinib + Osimertinib, Pemetrexed + Cisplatin /Carboplatin)

Recruiting
  • Non-small Cell Lung Cancer
  • Savolitinib + Osimertinib
  • Pemetrexed + Cisplatin /Carboplatin
  • Shanghai, Shanghai, China
    Shanghai Chest Hospital
Nov 29, 2021

Advanced Gastric Adenocarcinoma Trial in Seoul (AZD6094, docetaxel)

Completed
  • Advanced Gastric Adenocarcinoma
  • Seoul, Seoul, Korea, Republic Of, Korea, Republic of
    Samsung Medical Center
Jun 13, 2022

NSCLC, RET Driver Mutation, BRAF V600 Mutation Trial in Guanzhou (Toripalimab, Nab paclitaxel, Pemetrexed)

Recruiting
  • Non-Small Cell Lung Cancer
  • +5 more
  • Toripalimab
  • +3 more
  • Guanzhou, Guangdong, China
    Guangdong Lung Cancer Institute, Guangdong Provincial People's H
Apr 4, 2023

Stroke Trial in Chicago (High intensity gait training in a balance challenging Movement amplification environment)

Recruiting
  • Stroke
  • High intensity gait training in a balance challenging Movement amplification environment
  • Chicago, Illinois
    Northwestern University
Oct 20, 2023

Colorectal Cancer Metastatic, C-met Overexpression Trial in Rozzano (Tivantinib (ARQ197))

Completed
  • Colorectal Cancer Metastatic
  • C-met Overexpression
  • Tivantinib (ARQ197)
  • Rozzano, Milano, Italy
    Istituto Clinico Humanitas
Sep 8, 2022

NSCLC Trial in Japan, Korea, Republic of, Singapore (capmatinib, pemetrexed, cisplatin)

Terminated
  • Carcinoma, Non-Small-Cell Lung
  • Kashiwa, Chiba, Japan
  • +3 more
Jan 31, 2023

Behind Severe Insulin Resistance During Pregnancy in Glucose

Recruiting
  • Diabetes Mellitus, Type 2
  • +6 more
  • No interventions
  • Aarhus, Aarhus N, Denmark
  • +1 more
Nov 22, 2022

NSCLC Trial in Pittsburgh (Capmatinib)

Not yet recruiting
  • Non-small Cell Lung Cancer
  • Pittsburgh, Pennsylvania
    UPMC Hillman Cancer Center
Jan 9, 2023

Solid Tumor, MET Exon 14 Skipping Mutation, MET Amplification Trial in Korea, Republic of (Tepotinib)

Recruiting
  • Solid Tumor
  • +2 more
  • Hwasun, Chonnam, Korea, Republic of
  • +21 more
Nov 30, 2020

Head and Neck Squamous Cell Carcinoma Trial in Toronto (MET-4)

Active, not recruiting
  • Head and Neck Squamous Cell Carcinoma
  • Toronto, Ontario, Canada
    Princess Margaret Cancer Centre
Jan 8, 2023

Stomach Cancer, Adenocarcinoma Trial in Seoul (Durvalumab, Savolitinib)

Recruiting
  • Stomach Cancer, Adenocarcinoma
  • Seoul, Korea, Republic of
    Samsung Medical Center
Jan 10, 2023

NSCLC Metastatic Trial in Seoul (Lazertinib, Tepotinib)

Not yet recruiting
  • Non-Small Cell Lung Cancer Metastatic
  • Seoul, Gangnam-gu, Korea, Republic of
    Samsung Medical Center
Oct 27, 2023

Non Small Cell Lung Cancer (NSCLC), Metastases to the Brain Trial in Pittsburgh (cabozantinib)

Terminated
Has Results
  • Non Small Cell Lung Cancer (NSCLC)
  • Metastases to the Brain
  • Pittsburgh, Pennsylvania
    University of Pittsburgh Cancer Institute- Hillman Cancer Center
Mar 8, 2021

Lung Cancer, Anaplastic Lymphoma Kinase Gene Translocation, ROS1 Rearrangement Trial in Boston (Lorlatinib, Crizotinib,

Recruiting
  • Lung Cancer
  • +6 more
  • Boston, Massachusetts
  • +1 more
Mar 7, 2021

Brain Tumor Trial in Houston (tepotinib, tepotinib plus osimertinib)

Not yet recruiting
  • Brain Tumor
  • Houston, Texas
    M D Anderson Cancer Center
Jul 18, 2022

NSCLC Trial in Worldwide (Capmatinib, Amivantamab)

Not yet recruiting
  • Carcinoma, Non-Small-Cell Lung
  • Orange, California
  • +40 more
Aug 3, 2022

Advanced (Stage IIIB/IV) NSCLC (NSCLC) With MET Exon 14 (METex14) Skipping Alterations or MET Amplification Trial in Worldwide

Active, not recruiting
  • Advanced (Stage IIIB/IV) Non-small Cell Lung Cancer (NSCLC) With MET Exon 14 (METex14) Skipping Alterations or MET Amplification
  • Duarte, California
  • +140 more
Jun 7, 2022

Metastatic Breast Cancer, FGFR 1 High Amplification, FGFR2 Amplification Trial in Worldwide (Futibatinib, Futibatinib plus

Recruiting
  • Metastatic Breast Cancer
  • +2 more
  • Phoenix, Arizona
  • +36 more
Jan 27, 2023

Colorectal Tumors Trial in Worldwide (Tepotinib, Cetuximab)

Active, not recruiting
  • Colorectal Neoplasms
  • Phoenix, Arizona
  • +66 more
Nov 19, 2021

Negative T790M Mutation and Met Amplification Trial in Beijing (Glumetinib)

Unknown status
  • Negative T790M Mutation and Met Amplification
  • Beijing, Beijing, China
    Beijing Cancer Hospital
Apr 7, 2020